Tristel Regulatory News (TSTL)

4 Jul 2005 07:00

Tristel PLC04 July 2005 TRISTEL PLC Grant of Patent Tristel plc ("Tristel" or the "Company"), the AIM listed supplier of liquidchemical sterilising solutions to UK hospitals, announces that it has beengranted a patent for the Tristel Sterilising Wipes, the world's first rapidaction sporicidal wipe. Tristel markets a proprietary chlorine dioxide chemistry that is highlyeffective in destroying all types of bacteria (including bacterial spores,tuberculosis and MRSA), fungi and viruses and is one of a small group ofsporicidal agents that is safe and easy to use. The Wipe incorporates Tristel's patented chlorine dioxide chemistry. It can killall organisms on a pre-cleaned surface with a contact time of only 30 seconds.This means that medical instruments, such as ENT (Ear Nose & Throat) scopes andultrasound transducers, that cannot be immersed in liquid disinfectants, andcannot be sterilised by heat, can now be decontaminated easily, quickly andsafely. The Tristel Wipe system generates chlorine dioxide, a well documented, highlyeffective and safe biocide, by applying foam to the surface of the wipe which israpidly effective against all micro-organisms, including spores. The TristelSterilising Wipe is suitable for use in hospitals, laboratories, GP practices,dental practices and veterinary clinics. The Tristel Sterilising Wipe is farsuperior biocidally to a wipe that uses alcohol or any other availablechemistry. Tristel plc floated on AIM on 1 June 2005. Teather & Greenwood, NominatedAdvisor and Broker to Tristel, successfully raised £2.0m before expenses by wayof an institutional placing Tristel's core product range of instrument disinfectants has become the marketleader in the UK Acute & Private Hospital sector. They are used to decontaminateheat sensitive endoscopic and ultrasound instruments in over 375 hospitals,representing some 60 per cent of all UK NHS Acute & Private Hospitals. Contacts: Tristel plc Binns & Co PR LtdPaul Swinney Paul Barnes FCCA Paul McManusChief Executive Finance Director Tel: 020 7153 1485Tel: 01638 721 500 Tel: 01638 721 500 Mob: 07980 541 893 About the Company In 1998, the business that became Tristel acquired all world-wide rights to thepatented chemistry. The principal operating subsidiary of the Group wasestablished at this time to exploit the UK market. Tristel's products includeInstrument Solutions (primarily for flexible endoscopes), Instrument Wipes,Surface, Water and Skin Disinfectants. Tristel, based near Newmarket, Cambridgeshire, reported a pre-tax profit of£0.165m from a turnover of £2.18m for the year ended 30 June 2004. This information is provided by RNS The company news service from the London Stock Exchange